Patients with localized prostate cancer treated with primary androgen deprivation therapy (ADT) without radiation therapy or surgery derived no survival benefit, according to the results of a large study.
This slide show includes highlights from the 2014 Society of Gynecologic Oncology annual meeting, including one study showing bariatric surgery could lower the risk of uterine cancer, and another that found a PARP inhibitor active in BRCA-positive ovarian cancer.
Advanced melanoma patients treated with the anti–PD-1 inhibitor MK-3475 with tumors that expressed PD-L1 had higher survival rates and more robust immune responses compared with patients with tumors that did not express PD-L1.
In a phase I trial, non–small-cell lung cancer (NSCLC) patients with tumors that expressed PD-L1 had significantly better outcomes with MK-3475 therapy compared with patients with PD-L1–negative tumors.
New trial results show that a novel, oral metabolic inhibitor has demonstrated early activity in relapsed or refractory acute myeloid leukemia (AML), according to data presented at the annual meeting of the American Association of Cancer Research.